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Abstract 
Human serum albumin (HSA) derivatized with cis-aconitic anhydride (Aco-HSA) that was earlier shown to inhibit replication of 
human immunodeficiency virus type 1 (HIV-1), was covalently coupled to conventional liposomes, consisting of phosphatidylcholine, 
cholesterol and maleimido-4-(p-phenylbutyryl)phosphatidylethanolamine, using th  heterobifunctional reagent N-succinimidyl-S- 
acetylthioacetate (SATA). The amount of HSA that could be coupled to the liposomes depended on derivatization f the HSA and ranged 
from 64.2 +_ 9.2 /xg HSA//zmol total lipid for native HSA to 29.5 _+ 2.7/xg HSA//xmol total lipid for HSA in which 53 of the e amino 
groups of lysine were derivatized with cis-aconitic anhydride (Aco53-HSA). Incorporation of 3.8 mol% of total lipid of a poly(ethylene 
glycol) derivative of phosphatidylethanolamine (PEG-PE) in the liposomes resulted in a lower coupling efficiency of Aco-HSA. The 
elimination and distribution of the liposomal conjugates in rats in vivo was largely dependent on the modification of the HSA coupled to 
the liposomes. With native HSA-liposomes, more than 70% of the conjugate was still found in the blood plasma 30 min after i.v. injection 
in rats, while at this time Aco-HSA-liposomes were completely cleared from the circulation. The rapid clearance of conventional 
Aco-HSA-liposomes was due to a rapid uptake into the liver and could be considerably decreased by incorporating PEG-PE in the 
liposomal bilayer. After 3 h 60% of Aco-HSA-PEG-liposome conjugates were found in the blood. In an in vitro anti-HIV-1 assay, the 
50% inhibitory concentrations (ICso) for Aco39-HSA-liposomes and Ac%3-HSA-liposomes xpressed as protein weight, were 2.87 
/zg/ml and 0.154/xg/ml, respectively. When PEG-PE was incorporated, the Aco53-HSA-liposomes retained anti HIV-1 activity (IC~0: 
3.13 /~g/ml). The possibility to modulate the residence time in the bloodstream of Aco-HSA-liposomes and the potent anti-HIV-I 
activity of these conjugates, may allow the development of an intrinsically active drug carrier system. By incorporating anti HIV- 1 drugs 
such as AZT into such liposomes a drug delivery system can be designed that might act simultaneously on the virus/cell binding by 
virtue of the coupled Aco-HSA and on the RNA/DNA transcription of the HIV-I replication cycle through the nucleoside analogue. 
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1. Introduction 
Earlier we and others showed that human serum albu- 
mins (HSA) can be made highly negatively charged by 
derivatization of the e amino groups of lysine (through 
reaction with the anhydrides of succinic acid or cis-aconitic 
acid). These polyanionic proteins display a selective in 
vitro anti-human immunodeficiency virus type 1 (HIV-1) 
activity [1-3]. Especially HSA that has reacted with cis- 
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aconitic anhydride (Aco-HSA) proved to be a very potent 
inhibitor of HIV-l-induced cytopathogenicity [1]. The 
mechanism of action of these compounds i at the level of 
the binding and fusion of the virus with the target cells. 
The negatively charged HSA's have been proposed as 
potential carriers for 3'-azido-Y-deoxythymidine (AZT)- 
like drugs to T-lymphocytes and monocyte/macrophages. 
Such preparations may provide inhibition of HIV replica- 
tion at the level of virus/cell fusion, syncytium formation 
as well as RNA reverse transcription [4]. AZT in the 
monophosphate (AZT-MP) form can be coupled irectly to 
modified albumins yielding l to 6 molecules of AZT-MP 
per protein molecule [4]. Another approach to combine 
nucleoside analogues or other drugs with the negatively 
charged albumins, is by coupling these proteins to lipo- 
somes, which thus may function as high-capacity carriers 
for the chosen antiviral agent. 
Liposomes have been proven to be a suitable delivery 
system for various kinds of therapeutics, including immune 
modulators, cytostatics, virostatics and antimicrobial gents 
[5-9]. Liposomes have also been used as carriers for 
anti-HIV-1 nucleoside analogues [10] and for prodrugs of 
nucleoside analogues [11,12]. These and other studies have 
shown that the antiviral activity of liposomal anti-HIV-1 
nucleoside analogues can be preserved or even enhanced 
as compared to the free drug, while also reduced toxicity 
has been reported for such formulations [13]. Furthermore, 
the in vivo behaviour of liposomes can be modulated by 
incorporation of compounds like ganglioside GM1 or 
lipophilic derivatives of poly(ethylene glycol) to provide 
for a prolonged blood circulation time [14,15]. 
Several methods have been described for the covalent 
coupling of proteins to liposomes [16,17]. A widely used 
method, developed in our Institute, is based upon the 
reaction of sulfhydryl groups of thiolated proteins with 
maleimide residues incorporated in liposomes [18]. 
In this paper we describe the preparation of liposome 
conjugates of native HSA and of HSA, partially deriva- 
tized with cis-aconitic anhydride. Succinimidyl-S- 
thioacetate (SATA) was used to covalently couple the 
proteins to conventional orPEG-containing liposomes. The 
conjugates were chemically characterized and their dispo- 
sition in rats was subsequently investigated. To verify 
whether the Aco-HSA liposome conjugates had antiviral 
activity and could be potentially used for a dual attack on 
the HIV-1 life cycle, we determined the effect of HSA- 
coupled liposomes on HIV-1 replication in vitro. 
2. Materials and methods 
2.1. Materials 
Egg yolk phosphatidylcholine (PC), and maleimido-4- 
(p-phenylbutyryl)phosphatidylethanolamine (MPB-PE) 
were purchased from Avanti Polar lipids (Birmingham AL, 
USA). Human serum albumin fraction V (HSA) was ob- 
tained from the Central Laboratory of the Red Cross 
(Amsterdam, The Netherlands). Cholesterol (Chol), N- 
succinimidyl-S-acetylthioacetate (SATA) and cis-aconitic 
anhydride were from Sigma (St. Louis MO, USA). Iodine- 
125 (125I) and [3H]cholesteryloleyl ether were obtained 
from Amersham (Buckinghamshire, UK). Poly(ethylene 
glycol)-distearoylphosphatidylethanolamine (PEG-DSPE), 
synthesized from poly(ethylene glycol) with an average 
molecular weight of 1900 and distearoylphos- 
phatidylethanolamine, was a generous gift of Liposome 
Technology (Menlo Park, CA, USA) through Dr. T.M. 
Allen. All other chemicals were analytical grade or the 
best grade available. Polycarbonate filters for liposome 
extrusion were obtained from Costar (Cambridge, MA, 
USA). 
2.2. Methods 
2.2.1. Preparation of cis-aconitic anhydride modified hu- 
man serum albumin (Aco-HSA) 
Ten mg of HSA were dissolved in 10 ml 0.2 M 
K2HPO 4, pH 8.0. To obtain partially derivatized HSA's, 
variable amounts of solid cis-aconitic anhydride were 
added and the solution was stirred until all cis-aconitic 
anhydride was dissolved. The pH was kept at 8-8.5, using 
3 M NaOH. Modified HSA was purified by Sephadex 
G-50 filtration. The modified albumins were characterized 
by protein determination according to Lowry [19] and 
estimation of free e amino groups according to Habeeb 
[20]. The relative net charge of the modified albumins and 
the percentage monomers and dimers were determined as 
described before [1]. Shortly, this was done using a fast 
protein liquid chromatography (FPLC) system equipped 
with a mono-Q anion exchange column (Pharmacia; Upp- 
sala, Sweden) or a Superose-12 column (Pharmacia), re- 
spectively. HSA was produced in which 39.0 + 2.0 (mean 
+ S.D. of three batches) of the 60 e amino groups were 
derivatized with cis-aconitic anhydride (Aco39-HSA), and 
another in which 52.7 + 1.5 (mean + S.D. of three batches) 
of the • amino groups were derivatized (Aco53-HSA). 
2.2.2. Liposome preparation 
Lipids from stock solutions of PC, Chol and MPB-PE 
in chloroform/methanol (9:1), were mixed in a molar ratio 
of 23:16:1, dried under reduced nitrogen pressure, dis- 
solved in cyclohexane and lyophilized. The lipids were 
hydrated in HN-buffer (10 mM N-2-hydroxyethylpipera- 
zine-N'-2-ethanesulfonic acid (Hepes), 135 mM NaC1, pH 
6.7), under mechanical gitation. The liposomes were then 
sized by repeated extrusion (13 times) through polycarbon- 
ate filters (Costar, Cambridge MA, USA), pore size 50 nm, 
using a high pressure xtruder (Lipex, Vancouver, Canada). 
When appropriate, 0.04 mol PEGwoo-DSPE (PEG) was 
added to the lipid mixture per mol of phospholipid. When 
required, liposomes were radiolabeled with a tracer amount 
of [3H]cholesteryloleyl ther, which was included in the 
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lipid mixture during liposome preparation. Phospholipid 
phosphorus of each liposome preparation was assessed by 
phosphate assay after perchloric acid destruction [21]. To- 
tal liposomal ipid concentrations were adjusted for the 
amount of cholesterol present in the liposome preparations. 
Size and size distribution of the liposomes were deter- 
mined by dynamic laser light scattering with a Nicomp 
model 370 submicron particle analyzer (NICOMP particle 
sizing systems, Santa Barbara, CA, USA). The diameter of 
the liposome preparations was obtained from the volume 
distribution curves produced by the particle analyzer. 
2,2.3. Coupling of liSA or Aco-HSA to liposomes 
HSA or Aco-HSA was coupled to MPB-PE liposomes 
by a sulfhydryl-maleimide coupling technique as described 
before [18], with minor modifications. Briefly, free 
sulfhydryl groups were introduced in HSA or Aco-HSA, as 
described by Duncan et al. [22], using N-succinimidyl-S- 
acetylthioacetate (SATA) as a heterobifunctional reagent. 
After separation of free SATA from the protein by gel 
permeation chromatography, acetylthioacetate-(Aco)-HSA 
was deacetylated by addition of 100 /zl of a freshly 
prepared solution of 0.5 M hydroxylamine-HC1, 0.5 M 
Hepes, 25 mM EDTA, pH 7.0 per ml of protein solution 
and free sulfhydryl groups were determined according to 
Ellman [23]. After deacetylation, the thioacetyl-(Aco)-HSA 
was allowed to react for 4 h at room temperature with the 
MPB-PE containing liposomes in a ratio of 3 mg of 
protein per 10 /xmol total lipid. N-Ethylmaleimide (8 mM 
in HN buffer) was added to cap unreacted sulfhydryl 
groups [18]. Liposomes were separated from unconjugated 
protein by flotation on a metrizamide gradient. 2 ml of the 
liposome mixture were mixed with 2.5 ml of a 60% 
metrizamide solution containing 10 mM Hepes, 6.7 mM 
KC1 and 1.2 mM CaC12, pH 7.6. This solution was gently 
overlaid with 0.7 ml HN buffer and then centrifuged at 
150000 × g, 4°C, in a Beckman SW 50.1 swing out rotor. 
The liposomes were collected between the buffer and the 
metrizamide layer, after which the separation procedure 
was repeated. The protein-liposome conjugates were then 
extensively dialyzed against HN buffer, pH 7.4. Control 
liposomes were prepared from the same lipid mixture but, 
instead of being incubated with (Aco)-HSA, they were 
incubated with cysteine in a molar amount wice that of 
MPB-PE to block reactive maleimido groups on the lipo- 
some surface. The (Aco)-HSA-liposome conjugates were 
characterized by determining protein [24] and phospholipid 
phosphorus content [21] and by particle size analysis. In 
some experiments HSA was labeled with 125I as described 
by McFarlane [25] before starting the coupling procedure. 
Experiments with the (Aco)-HSA-liposome conjugates 
were performed within 1 week after preparation. 
2.2.4. Serum disappearance, liver uptake and tissue distri- 
bution of liposomes 
When in vivo experiments were performed with a dura- 
tion of 30 min, male Wag-Rij rats (200-250 g) were 
anaesthetized by intraperitoneal injection of 20-25 mg 
sodium pentobarbital. Radiolabeled liposomes were in- 
jected via the penile vein and the abdomen was opened. As 
100% value for the injected dose the actual amount of 
radioactivity injected was taken (corrected for radioactivity 
remaining in the needle, syringe and tube). At the indi- 
cated times, blood samples were taken from the inferior 
vena cava and allowed to clot for 60 rain, at 4°C. The 
samples were centrifuged (5' at 13000×g).  The total 
amount of radioactivity in the serum was calculated using 
the equation: serum volume (ml) = (0.0219 × body weight 
(g)) + 2.66 [26]. At the indicated times, liver lobules were 
excised and weighed. The total amount of liver tissue tied 
off did not exceed 15% of the total liver weight. Radioac- 
tivity in the liver was corrected for radioactivity present in 
serum at the time of sampling (85 /xl serum/g of wet 
weight) [27]. When indicated, other tissues were removed 
and weighed at the end of the experiment. The tissues were 
homogenized using a Potter Elvehjem tube. Radioactivity 
was determined after solubilization of 0.4 ml of the ho- 
mogenate in 100 /xl 10% SDS and 4 ml scintillation 
cocktail. Radioactivity in the tissues was corrected for 
radioactivity originating from their plasma contents [27]. 
When experiments were performed with PEG-liposomes, 
rats were injected via the penile vein under light dieth- 
ylether anesthesia. At the indicated time points blood 
samples were taken from the tail vein. At 3 h the rats were 
anesthetized and liver and spleen were removed and treated 
as described above. 
2.2.5. Cells and virus 
MT-4 cells, a T 4 lymphocyte cell line harbouring hu- 
man T-cell lymphotropic virus type-1 (HTLV-1) [28], were 
used for the anti-HIV-1 assay. The MT-4 cells were grown 
in RPMI 1640 medium supplemented with 10% (v/v)  
heat-inactivated fetal calf serum and 20 /xg/ml gen- 
tamycin. The cells were maintained at 37°C in a humidi- 
fied atmosphere of 5% CO 2 in air. Every 3-4 days, cells 
were centrifuged and seeded at 2.105 cells/ml in new 
culture flasks. At regular time intervals, the cells were 
analyzed for the presence of mycoplasma and were consis- 
tently found to be mycoplasma free. HIV-1 (strain HTLV- 
III B) [29] was obtained from the culture supernatant of 
persistently HIV-1 infected HUT-78 cells. The virus titer 
of the supernatant was determined in MT-4 cells. The virus 
stock was stored at -70°C until used. 
2.2.6. Antiviral assay 
Antiviral activity of the test compounds was assessed 
by measurement of viability of MT-4 cells that had been 
infected or not infected with HIV-1 and exposed to various 
concentrations of the test compounds. The viability of the 
cells was examined spectrophotometrically by the 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro ide 
(MTT) method as described in more detail previously [30]. 
The cytotoxicity of the compounds was also monitored by 
the MTT assay. 
186 J.A.A.M. Kamps et al. / Biochimica et Biophysica Acta 1278 (1996) 183-190 
Table 1 
Characterization f conventional liposomes and PEG-liposomes 
Protein tool SATA/  Liposome diameter Protein/lipid ratio 
coupled tool HSA (nm) (/xg/k~mol TL) 
Conventional liposomes 
none - 74.7 + 1.1 - 
HSA 5.4+0.7 131.1-1-6.5 64.2+9.2 
Aco39-HSA 4.5+0.6 85.8+1.5 35.2+3.7 
Aco53-HSA 4.8-1-0.6 92.0_+4.3 29.5_+2.7 
PEG-liposomes 
none - 77.4 + 1.4 - 
Aco39-HSA 4.5_+0.6 96.3-1-8.5 20.3_+1.9 
Aco53-HSA 4.8_+0.6 87.8_+2.6 22.9_+2.3 
The liposomes were characterized as described in Section 2. TL is total 
lipid. The data are presented as means-I-S.E, of 4-12 liposome prepara- 
tions. 
2.2.7. Statistical evaluation 
Statistical significance of differences was evaluated by 
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Fig. 1. Serum disappearance and liver uptake of control liposomes (O) 
and HSA-liposomes (11, []). Liposomes, which were labeled in the lipid 
moiety with [3H]cholesteryloleyl ether (. ,11) or in the protein moiety 
with 1251 ([]), were injected into anesthetized rats. Radioactivity in serum 
( ) and liver (---) samples was determined asdescribed in
Section 2. Values are means of at least wo rats. 
3.  Resu l ts  
3.1. Synthesis and characterization of (Aco)-HSA-lipo- 
somes 
(Aco)-HSA was coupled to MPB-PE-containing lipo- 
somes with a diameter of 74.7 nm after extrusion through 
50-nm polycarbonate filters (Table 1). When 3.8 mol% of 
total lipid PEG-DSPE was incorporated into the liposomes, 
a diameter of 77.4 nm was obtained after extrusion. Cou- 
pling of the different HSA preparations to the liposomes 
led to a significant increase of the particle diameter (P  < 
0.05) in all cases. Coupling of the heterobifunctional 
reagent SATA to the proteins resulted in the introduction 
of 4.5 to 5.4 sulfhydryl groups. Per albumin molecule the 
number of sulfhydryl groups introduced in the protein 
tended to decrease with the degree of derivatization with 
cis-aconific anhydride. The amount of protein that could be 
coupled to the liposomes was therefore higher for native 
HSA than for Aco-HSA. For native HSA-liposomes a 
number 45 HSA molecules per liposome was calculated, 
assuming a molecular weight of HSA of 69 000 and assum- 
ing that 1 /zmol liposomal ipid contains 48 000 liposomes 
[31]. Derivatization of HSA with either 39 molecules or 53 
molecules of cis-aconitic anhydride did not significantly 
affect the amount of protein that could be coupled to either 
liposome type. However, slightly more Aco-HSA could be 
coupled covalently to conventional liposomes as compared 
to the PEG-liposomes. 
The liposome conjugates were stable for at least 4 
weeks at 4°C, with respect o size and to the amount of 
protein coupled. The in vivo stability of the conjugates was 
determined by comparing the liver uptake and serum decay 
of HSA-liposome conjugates which were either labeled in 
the lipid moiety with [3H]cholesteryloleyl ether or in the 
protein moiety with 1251 (Fig. 1). The in vivo behaviour of 
the conjugates was independent of the type of label. Con- 
trol liposomes, without coupled protein, showed a slower 
blood clearance and hepatic uptake. 
3.2. Effect of coupled Aco39-HSA and Aco53-HSA on the 
serum disappearance of liposomes 
The plasma disappearance of conventional control lipo- 
somes, Aco39-HSA-liposomes and Acos3-HSA-liposomes 
is shown in Fig. 2. Injection of either one Aco-HSA-lipo- 
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Fig. 2. Serum disappearance of control liposomes (0), Aco39-HSA-lipo- 
somes (O) and Aco53-HSA-liposomes (•). [3H]Cholesteryloleyl ether- 
labeled liposomes were injected into anesthetized rats. Blood samples 
were taken and radioactivity was determined asdescribed in Section 2. 
Values are means -t- S.D. of 3-5 rats. 
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Fig. 3. Serum disappearance of control PEG-DSPE-liposomes (O), 
Aco39-HSA-PEG-liposomes ((3) and Aco53-HSA-PEG-liposomes (A). 
[3H]Cholesteryloleyl ether-labeled liposomes were injected into anes- 
thetized rats. Blood samples were taken and radioactivity was determined 
as described in Section 2. Values are means + S.D. of 3-5 rats. 
conjugates, as compared to control liposomes. At 10 rain 
after injection, more than 95% of both the Aco39-HSA and 
Aco53-HSA-liposomes had disappeared from the blood 
plasma, while with control liposomes 88% was still pre- 
sent. There was no significant difference in clearance 
between Aco39-HSA and Ac%3-HSA-liposomes. Incorpo- 
ration of 3.8 mol% of total lipid PEG-DSPE in the lipo- 
somes could largely overcome the fast clearance from the 
circulation of conventional Aco-HSA-liposomes (Fig. 3). 
At 30 min after injection 85% of the injected dose of 
Aco39-HSA-PEG-liposomes and 70% of Aco53-HSA- 
PEG-liposomes were still present in the blood. In the first 
30 min after injection of the conjugates, there was a 
significant difference in the plasma levels of Aco39-HSA- 
PEG-liposomes and Aco53-HSA-PEG-liposomes (P< 
0,005), while after this time point the clearance of the two 
conjugates from the plasma was comparable up to 3 h. 
After 3 h of circulation about 60% of the Aco-HSA-PEG- 
liposomes was still found in the plasma, while about 70% 
of the control iposomes was recovered from the blood. 
3.3. Tissue distribution of Aco-HSA-liposomes 
The [3H]cholesteryloleyl ether-labeled Aco-HSA-lipo- 
somes were mainly recovered in the liver and to a lesser 
extent in the spleen (Table 2). Other organs tested for 
radioactivity, such as kidney, lung and heart, did not show 
any significant uptake of Aco-HSA-liposomes (results not 
shown). At 30 min after i.v. injection of the conventional 
Aco39-HSA- and Aco53-HSA-liposomes, 80% was taken 
up by the liver, while the spleen accounted for 3% of the 
injected dose of these liposomes. When PEG-DSPE was 
incorporated in the Aco-HSA-liposomes, the liver re- 
mained the main site of uptake. However, at 3 h after 
administration of Aco39-HSA- or Aco53-HSA-PEG-lipo- 
Table 2 
Tissue distribution of 
HSA-PEG)-liposomes 
conventional (Aco-HSA)-liposomes and (Aco- 
Liposome Time Distribution (% of injected ose) 
composition (min) spleen liver serum 
C-lip 30 4.6+3.3 4.9+ 5.6 80.2+4.9 
Aco39-HSA-li p 30 2.9+0.5 79.8+ 18.3 2.5+3.6 
Aco53-HSA-li p 30 3.1 + 1.5 79.6+20.0 2.8+3.4 
PEG-lip 180 9.1 +0.9 4.2+ 2.1 70.0+2.6 
Aco39-HSA-PEG-Ii p 180 3.2+0.3 21.9+ 0.9 62.3+1.8 
Aco53-HSA-PEG-Ii p 180 2.6+0.7 26.6+ 3.3 57.7+5.8 
[3H]Cholesteryloleyl ether-labeled liposomes were injected into anes- 
thetized rats. Radioactivity in the different issues was determined at the 
indicated time after injection as described in Section 2. Data are presented 
as means + S.D. of 3-5 experiments. C-lip is control liposome. 
somes, only 22% and 27% of the injected ose were found 
liver-associated, respectively. Spleen uptake of Aco-HSA- 
PEG-liposomes was lower than of control PEG-liposomes, 
but in the same range as that found for Aco-HSA-lipo- 
somes. Control PEG-liposomes were taken up by the spleen 
to a two-fold larger extent han by the liver, in line with 
earlier observations [32]. The total recovery of radioactiv- 
ity from the tissues and fluids studied was always higher 
than 85% of the injected ose. 
3.4. Anti-HIV-I activity of Aco-HSA-Iiposomes 
Table 3 shows the antiviral activities of Aco39-HSA, 
Aco53-HSA and the different Aco-HSA liposome conju- 
gates tested against HIV-1, in vitro. The IC50 values of the 
conventional Aco39-HSA and Aco53-HSA liposomes were 
2.87 and 0.15 /xg of protein/ml, respectively. Free Aco39-  
HSA and Aco53-HSA were 3 to 4 times more effective 
against HIV-1 replication in MT4 cells than the liposomal 
conjugates. Incorporation of PEG-DSPE in the liposomes 
resulted in a significant loss of antiviral activity of the 
Aco-HSA liposome conjugates, but with Aco53-HSA- 
PEG-liposomes still an IC50 of 3.13 /xg of protein/ml was 
obtained. Aco39-HSA-PEG-liposomes did not show appre- 
Table 3 
Inhibitory effects of the compounds on HIV-l-induced cytopathogenicity 
Compound IC5o (/zg CC5o (/zg SI 
protein/ml) protein/ml) 
HSA > 250 > 250 > < 1 
Aco39-HSA 1.080 > 250 > 234 
Aco53-HSA 0.037 > 250 > 7011 
Aco39-HSA-li p 2.865 > 4 > 52-126 
Aco53-HSA-Ii p 0.154 > 12 > 53-277 
Aco39-HSA-PEG-li p n.a. - - 
Aco53-HSA-PEG-Ii p 3.131 > 8 > 3 
ICs0 is the concentration needed to obtain 50% inhibition of virus-in- 
duced pathogenicity. CC50 is the concentration needed for 50% reduction 
of cell viability due to the compounds. SI is the selectivity index 
(CC50/IC50). n.a., not active (no anti-HIV-1 activity could be detected). 
Data are mean values of 2-4 determinations from two separate xperi- 
ments. 
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ciable anti-HIV-1 activity. Control iposomes without Aco- 
HSA coupled, did not show any anti-HIV-1 activity (re- 
suits not shown). The conjugates did not appear to be 
cytotoxic to MT4 cells at the concentrations u ed in the 
anti-HIV-1 assay. However, the cell toxicity (CC50) and 
the selectivity index (SI) of the liposomal formulations 
could not be accurately determined, since the limited 
amount of protein that can be coupled to the liposomes did 
not allow testing of high protein concentrations in the 
cytotoxicity assay. 
4. Discussion 
In this report we describe the preparation and charac- 
terization of a liposomal drug carrier system with a potent 
intrinsic anti-HIV-1 activity. HSA and negatively charged 
Aco-HSA were covalently coupled to small type liposomes 
using the heterobifunctional reagent N-succinimidyl-S- 
acetylthioacetate. This is a well established method for 
coupling proteins to liposomes, based upon the reaction of 
thiolated proteins and liposomal maleimido-4-(p-phenyl- 
butyryl)phosphatidylethanolamine [18,33,34]. The number 
of sulfhydryl groups that could be introduced in HSA or 
Aco-HSA was reproducible. Thiolation of Aco53-HSA, in 
which 53 of the free e-amino groups of lysine were 
derivatized with cis-aconit ic anhydride, still allowed the 
introduction of 4.8 sulfhydryl molecules in this protein. 
This indicates that SATA is also very suitable for coupling 
highly derivatized proteins to liposomes. The amount of 
protein that could be coupled to the liposomes was signifi- 
cantly lower for the Aco-HSA than for native HSA. This 
may be due to the relatively strong negative charge of 
Aco-HSA [1], which may cause electrostatic repulsion. 
Incorporation of PEG-DSPE in the liposomes resulted in a 
slightly lower coupling efficiency of Aco-HSA. This is 
probably caused by steric hindrance by PEG at the lipo- 
some surface. Taking in account the serum decay and liver 
uptake patterns of HSA-liposomes, which were labeled 
either with 1251 in the protein moiety or with [3H]choles- 
teryloleyl ether in the lipid moiety, it can be concluded that 
the covalent bond between the liposome and the coupled 
protein remains intact in the circulation. 
Both Aco39-HSA- and Aco53-HSA-liposomes are 
rapidly cleared from the blood, while control liposomes 
show a very slow plasma disappearance. The rapid re- 
moval of the Aco-HSA-liposomes from the blood stream is 
associated with a high liver uptake. Spleen uptake of the 
liposomes was not affected by coupling of Aco-HSA. Low 
amounts of negatively charged succinylated HSA (Suc- 
HSA) [35] and Aco-HSA (Swart, P.J. et al., unpublished 
data) have also been shown to be taken up rapidly by the 
liver. This further substantiates that the in vivo behaviour 
of the Aco-HSA-liposomes i determined predominantly 
by the coupled protein and not by the lipid part of the 
conjugate. 
Incorporation of phospholipid erivatives of PEG in 
liposomes has been shown to prolong the blood circulation 
time of liposomes [15]. Inhibition of the specific and/or 
non specific interaction between PEG modified liposomes 
and the mononuclear phagocyte system have been invoked 
to explain these favourable characteristics. At 3 h after 
injection of Aco39-HSA-PEG- and Ac%3-HSA-PEG-lipo- 
somes blood concentrations were only 10% lower than the 
blood levels of control PEG-liposomes at that time. This 
indicates that incorporation of 3.8 mol% of total lipid 
PEG1900-DSPE in the liposomes can largely overcome the 
effect of Aco-HSA on the residence time in the blood 
stream. Similar to what we observed with the conventional 
liposomes, the clearance of Aco-HSA-PEG-liposomes i
mainly due to liver uptake of the conjugates. However, as 
compared to control PEG-liposomes the uptake by the 
spleen is significantly lower for Aco-HSA-PEG-liposomes 
than for control PEG-liposomes. This might be explained 
by the active involvement of the scavenger removal system 
in rat liver. Negatively charged proteins, including nega- 
tively charged HSA, have been demonstrated to be taken 
up very efficiently by the liver through scavenger receptors 
on liver endothelial cells and Kupffer cells [36]. When 
Aco-HSA-PEG-liposomes are accommodated by such 
scavenger receptors, this may cause a shift from splenic to 
hepatic uptake as compared to control PEG-liposomes. 
Recently, it has been shown that Aco-HSA, with an 
IC50 of 0.02 /zg/ml, is one of the most potent in vitro 
anti-HIV-1 agents described to date [1]. Furthermore Aco- 
HSA does not show unwanted side effects, such as anti- 
coagulant activity, which has been described for dextran 
sulfate, a polyanion which also exhibits anti-HIV-1 activity 
[1]. The antiviral effect of Aco-HSA is rather specific for 
HIV-1 and the mechanism of action appears to be at the 
level of virus-cell binding and particularly on the fusion of 
the virus with the cell membrane. It has been postulated 
that these negatively charged albumins interact with the gp 
41 envelope glycoprotein or may bind to the V3 loop of gp 
120 [4]. These results were obtained with Aco-HSA in 
which all 60 amino groups of lysine were derivatized with 
cis-aconit ic anhydride. The present study shows that the 
partially derivatized Aco39-HSA and Aco53-HSA still dis- 
play a potent anti-HIV-1 activity of 1.08 /xg/ml and 0.04 
/~g/ml, respectively. The observed ifference in anti-HIV- 
1 activity between fully derivatized HSA and partially 
derivatized HSA indicates that the activity of these pro- 
teins is dependent on the degree of derivatization. This 
finding is in agreement with data which show that the 
anti-viral effect of negatively charged proteins correlates 
directly with the density of negative charges [3]. 
After coupling to conventional liposomes, the acylated 
proteins retain their anti-HIV-1 activity, although the an- 
tiviral activity decreases. When PEG-DSPE was incorpo- 
rated in the liposomal bilayer no anti-HIV-1 activity could 
even be detected for Aco39-HSA-PEG-liposomes, but for 
Ac%3-HSA-PEG liposomes till an IC5o of 3.13 /zg/ml 
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was found. Since there is no significant physicochemical 
difference between Aco39-HSA-PEG l iposomes and 
Aco53-HSA-PEG liposomes we suggest hat the difference 
in antiviral activity is due to differences in acylation, while 
the decrease in anti-HIV activity as compared to conven- 
tional Aco-HSA liposomes may be caused by steric hin- 
drance of the poly(ethylene glycol) on the surface of the 
liposomes. 
With Aco53-HSA-PEG-liposomes a dual attack on the 
life cycle of HIV-1 might be accomplished: firstly, on the 
binding/fusion of the virus with the cell membrane by 
means of the coupled Aco-HSA and, secondly, on the 
reverse transcriptase by including anti-HIV-1 nucleoside 
analogues. Apart from a potential dual attack on virus 
replication, there is evidence of synergistic effects of 
polyanionic ompounds and nucleoside analogues [37,38]. 
It is of interest that in a previous report [39] liposomal 
preparations were described with an anti-HIV activity in 
which charge modification was not obtained by coupling 
of polyanionic proteins, but through inclusion of nega- 
tively charged lipids. The present results confirm the abil- 
ity of net negatively charged liposomes to inhibit HIV-1 
replication in vitro. 
Since Aco53-HSA-PEG liposomes have a long circula- 
tion time in blood, this conjugate may prove to be attrac- 
tive as carriers for anti-HIV-agents to T-lymphocytes and 
monocytes/macrophages.  Macrophages have been shown 
to endocytose polyanionic molecules including acylated 
proteins. Recent studies also indicate the presence of bind- 
ing sites for negatively charged proteins on T-lymphocytes 
[4]. Recently, it was reported that both liver parenchymal 
and sinusoidal cells can be infected by HIV-1 in vivo [40]. 
In general, l iposomes are avidly taken up by the liver, 
especially by the macrophages. Therefore, since both con- 
ventional as well as Aco-HSA-PEG-l iposomes are, at least 
to some extent, taken up by the liver, they may be suitable 
carriers for the targeting of anti-HIV-1 drugs to various 
liver cells. We are currently investigating the mechanisms 
by which liver cell types take up Aco-HSA-l iposome 
conjugates. 
In conclusion, the procedure for coupling Aco-HSA to 
l iposomes is reproducible and the conjugates eem to be 
stable after injection in vivo. The possibility to modulate 
the in vivo disposition of Aco-HSA-l iposomes combined 
with the anti-HIV-1 activity of these conjugates, allows the 
development of a potent drug carrier system with a dual 
anti HIV-I activity. Currently, studies are in progress in 
our laboratories to determine possible synergistic antiviral 
effects of anti-HIV-1 nucleoside analogues and Aco-HSA- 
liposomes as their delivery system. 
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